KOL Data

Sales & Marketing

As biopharmas increasingly rely on AI and advanced data-driven technologies, evaluating the quality of data is critical.

Partner Content

how to navigate through KOL insights & management

News

Chiesi has boosted its rare disease business with an agreement to buy KalVista and Ekterly, its oral drug for treating attacks in rare disease HAE.

Sales & Marketing

As AI continues to reshape the healthcare landscape, pharma teams are beginning to leverage synthetic personas.